Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Defective lymphatic valve development and chylothorax in mice with a lymphatic-specific deletion of Connexin43.

Munger SJ, Davis MJ, Simon AM.

Dev Biol. 2017 Jan 15;421(2):204-218. doi: 10.1016/j.ydbio.2016.11.017.

PMID:
27899284
2.

Lymphatic pumping: mechanics, mechanisms and malfunction.

Scallan JP, Zawieja SD, Castorena-Gonzalez JA, Davis MJ.

J Physiol. 2016 Oct 15;594(20):5749-5768. doi: 10.1113/JP272088.

PMID:
27219461
3.

Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice.

Munger SJ, Geng X, Srinivasan RS, Witte MH, Paul DL, Simon AM.

Dev Biol. 2016 Apr 15;412(2):173-90. doi: 10.1016/j.ydbio.2016.02.033.

PMID:
26953188
4.

Combining Foxc2 and Connexin37 deletions in mice leads to severe defects in lymphatic vascular growth and remodeling.

Kanady JD, Munger SJ, Witte MH, Simon AM.

Dev Biol. 2015 Sep 1;405(1):33-46. doi: 10.1016/j.ydbio.2015.06.004.

5.

Gap junction coupling is required for tumor cell migration through lymphatic endothelium.

Karpinich NO, Caron KM.

Arterioscler Thromb Vasc Biol. 2015 May;35(5):1147-55. doi: 10.1161/ATVBAHA.114.304752.

6.

VEGF-C improves regeneration and lymphatic reconnection of transplanted autologous lymph node fragments: An animal model for secondary lymphedema treatment.

Schindewolffs L, Breves G, Buettner M, Hadamitzky C, Pabst R.

Immun Inflamm Dis. 2014 Nov;2(3):152-61. doi: 10.1002/iid3.32.

7.

Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction.

Agollah GD, Gonzalez-Garay ML, Rasmussen JC, Tan IC, Aldrich MB, Darne C, Fife CE, Guilliod R, Maus EA, King PD, Sevick-Muraca EM.

PLoS One. 2014 Nov 10;9(11):e112548. doi: 10.1371/journal.pone.0112548.

8.

New developments in clinical aspects of lymphatic disease.

Mortimer PS, Rockson SG.

J Clin Invest. 2014 Mar;124(3):915-21. doi: 10.1172/JCI71608. Review.

9.

Genetics of lymphatic anomalies.

Brouillard P, Boon L, Vikkula M.

J Clin Invest. 2014 Mar;124(3):898-904. doi: 10.1172/JCI71614. Review.

10.

Development of the mammalian lymphatic vasculature.

Yang Y, Oliver G.

J Clin Invest. 2014 Mar;124(3):888-97. doi: 10.1172/JCI71609. Review.

11.

Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema.

Mendola A, Schlögel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastré E, Bygum A, van der Vleuten C, Fagerberg C, Baselga E, Quere I, Mulliken JB, Boon LM, Brouillard P, Vikkula M; Lymphedema Research Group..

Mol Syndromol. 2013 Sep;4(6):257-66. doi: 10.1159/000354097.

12.

Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature.

Dellinger MT, Meadows SM, Wynne K, Cleaver O, Brekken RA.

PLoS One. 2013 Sep 2;8(9):e74686. doi: 10.1371/journal.pone.0074686.

13.

Evaluation of Clinical Manifestations in Patients with Severe Lymphedema with and without CCBE1 Mutations.

Alders M, Mendola A, Adès L, Al Gazali L, Bellini C, Dallapiccola B, Edery P, Frank U, Hornshuh F, Huisman SA, Jagadeesh S, Kayserili H, Keng WT, Lev D, Prada CE, Sampson JR, Schmidtke J, Shashi V, van Bever Y, Van der Aa N, Verhagen JM, Verheij JB, Vikkula M, Hennekam RC.

Mol Syndromol. 2013 Mar;4(3):107-13. doi: 10.1159/000342486.

14.

Absence of venous valves in mice lacking Connexin37.

Munger SJ, Kanady JD, Simon AM.

Dev Biol. 2013 Jan 15;373(2):338-48. doi: 10.1016/j.ydbio.2012.10.032.

15.

Flow control in our vessels: vascular valves make sure there is no way back.

Bazigou E, Makinen T.

Cell Mol Life Sci. 2013 Mar;70(6):1055-66. doi: 10.1007/s00018-012-1110-6. Review.

16.

Vascular anomalies: from genetics toward models for therapeutic trials.

Uebelhoer M, Boon LM, Vikkula M.

Cold Spring Harb Perspect Med. 2012 Aug 1;2(8). pii: a009688. doi: 10.1101/cshperspect.a009688. Review.

17.

The new era of the lymphatic system: no longer secondary to the blood vascular system.

Choi I, Lee S, Hong YK.

Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006445. doi: 10.1101/cshperspect.a006445. Review.

18.

Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment.

Finegold DN, Baty CJ, Knickelbein KZ, Perschke S, Noon SE, Campbell D, Karlsson JM, Huang D, Kimak MA, Lawrence EC, Feingold E, Meriney SD, Brufsky AM, Ferrell RE.

Clin Cancer Res. 2012 Apr 15;18(8):2382-90. doi: 10.1158/1078-0432.CCR-11-2303.

19.

Lymphatic communication: connexin junction, what's your function?

Kanady JD, Simon AM.

Lymphology. 2011 Sep;44(3):95-102. Review.

20.

Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.

Kazenwadel J, Secker GA, Liu YJ, Rosenfeld JA, Wildin RS, Cuellar-Rodriguez J, Hsu AP, Dyack S, Fernandez CV, Chong CE, Babic M, Bardy PG, Shimamura A, Zhang MY, Walsh T, Holland SM, Hickstein DD, Horwitz MS, Hahn CN, Scott HS, Harvey NL.

Blood. 2012 Feb 2;119(5):1283-91. doi: 10.1182/blood-2011-08-374363.

Supplemental Content

Support Center